Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

被引：27

作者：

Cortes, Jorge E.

Tallman, Martin S.

Schiller, Gary

Trone, Denise

Gammon, Guy

Goldberg, Stuart

Perl, Alexander E.

Marie, Jean Pierre

Martinelli, Giovanni

Levis, Mark

机构：

来源：

BLOOD | 2013年 / 122卷 / 21期

关键词：

D O I：

10.1182/blood.V122.21.494.494

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

494

引用

页数：2

共 50 条

[41] TYROSINE KINASE INHIBITORS (TKI) IN RELAPSED/REFRACTORY (RR) PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) CONFER BETTER SURVIVAL THAN CHEMOTHERAPY, DUE TO A BETTER SAFETY PROFILE [J].

Marconi, G. ;

De Polo, S. ;

Ottaviani, E. ;

Paolini, S. ;

Bochicchio, M. T. ;

Nanni, J. ;

Bertamini, L. ;

Abbenante, M. C. ;

Sartor, C. ;

Parisi, S. ;

Talami, A. ;

Olivi, M. ;

Ragaini, S. ;

Raffini, M. ;

Baldazzi, C. ;

Testoni, N. ;

Cavo, M. ;

Curti, A. ;

Martinelli, G. ;

Papayannidis, C. .

HAEMATOLOGICA, 2018, 103 :S100-S101

[42] Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial [J].

Jonas, Brian A. ;

Cortes, Jorge E. ;

Khaled, Samer K. ;

Martinelli, Giovanni ;

Perl, Alexander E. ;

Ganguly, Siddhartha ;

Russell, Nigel H. ;

Kraemer, Alwin ;

Dombret, Herve ;

Hogge, Donna ;

Leung, Anskar Y. -H. ;

Mehta, Priyanka ;

Montesinos, Pau ;

Radsak, Markus P. ;

Sica, Simona ;

Arunachalam, Meena ;

Holmes, Melissa ;

Kobayashi, Ken ;

Namuyinga, Ruth ;

Ge, Nanxiang ;

Yver, Antoine ;

Zhang, Yufen ;

Levis, Mark J. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S221-S222

[43] A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia. [J].

Perl, Alexander E. ;

Cortes, Jorge E. ;

Strickland, Stephen Anthony ;

Ritchie, Ellen K. ;

Neubauer, Andreas ;

Martinelli, Giovanni ;

Naoe, Tomoki ;

Pigneux, Arnaud ;

Rousselot, Philippe H. ;

Rollig, Christoph ;

Baer, Maria R. ;

Larson, Richard A. ;

James, Angela Joubert ;

Chen, Caroline ;

Shu, Lei ;

Hasabou, Nahla ;

Bahceci, Erkut .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[44] A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia [J].

Sweet, Kendra ;

Bhatnagar, Bhavana ;

Dohner, Hartmut ;

Donnellan, Will ;

Frankfurt, Olga ;

Heuser, Michael ;

Kota, Vamsi ;

Liu, Hongtao ;

Raffoux, Emmanuel ;

Roboz, Gail J. ;

Rollig, Christoph ;

Showel, Margaret M. ;

Strickland, Stephen A. ;

Vives, Susana ;

Tang, Shijie ;

Unger, Thaddeus J. ;

Joshi, Anita ;

Shen, Yao ;

Alvarez, Mariano J. ;

Califano, Andrea ;

Crochiere, Marsha ;

Landesman, Yosef ;

Kauffman, Michael ;

Shah, Jatin ;

Shacham, Sharon ;

Savona, Michael R. ;

Montesinos, Pau .

LEUKEMIA & LYMPHOMA, 2021, 62 (13) :3192-3203

[45] Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome [J].

Assi, Rita ;

Kantarjian, Hagop M. ;

Kadia, Tapan M. ;

Pemmaraju, Naveen ;

Jabbour, Elias ;

Jain, Nitin ;

Daver, Naval ;

Estrov, Zeev ;

Uehara, Taisuke ;

Owa, Takashi ;

Cortes, Jorge E. ;

Borthakur, Gautam .

CANCER, 2018, 124 (13) :2758-2765

[46] Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial [J].

Cortes, Jorge E. ;

Khaled, Samer K. ;

Martinelli, Giovanni ;

Perl, Alexander E. ;

Ganguly, Siddhartha ;

Russell, Nigel H. ;

Kramer, Alwin ;

Dombret, Herve ;

Hogge, Donna ;

Jonas, Brian A. ;

Leung, Anskar Y. -H. ;

Mehta, Priyanka ;

Montesinos, Pau ;

Radsak, Markus P. ;

Sica, Simona ;

Arunachalam, Meena ;

Holmes, Melissa ;

Kobayashi, Ken ;

Namuyinga, Ruth ;

Ge, Nanxiang ;

Yver, Antoine ;

Zhang, Yufen ;

Levis, Mark J. .

BLOOD, 2018, 132

[47] Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study [J].

Perl, Alexander E. ;

Altman, Jessica K. ;

Cortes, Jorge ;

Smith, Catherine ;

Litzow, Mark ;

Baer, Maria R. ;

Claxton, David ;

Erba, Harry P. ;

Gill, Stan ;

Goldberg, Stuart ;

Jurcic, Joseph G. ;

Larson, Richard A. ;

Liu, Chaofeng ;

Ritchie, Ellen ;

Schiller, Gary ;

Spira, Alexander I. ;

Strickland, Stephen A. ;

Tibes, Raoul ;

Ustun, Celalettin ;

Wang, Eunice S. ;

Stuart, Robert ;

Roellig, Christoph ;

Neubauer, Andreas ;

Martinelli, Giovanni ;

Bahceci, Erkut ;

Levis, Mark .

LANCET ONCOLOGY, 2017, 18 (08) :1061-1075

[48] Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3-ITD/ NPM1wt Patients - a Study By the NOPHO-DB-SHIP Consortium [J].

Kaspers, Gertjan J. L. ;

Wijnen, Noa E. ;

Koedijk, Joost B. ;

Ishimaru, Sae ;

Benedictus, Renske ;

Van Opstal, Ellen C. ;

Van Tinteren, Harm ;

Zwaan, C. Michel ;

Biserna, Noha ;

Downs, Pamela ;

Duong, Yvonne ;

Kamel, Yasser Mostafa ;

Abrahamsson, Jonas ;

Arad-Cohen, Nira ;

Bodmer, Nicole ;

Castillo, Luis ;

Cheuk, Daniel ;

Costa, Vitor ;

De Moerloose, Barbara ;

Fernandez Navarro, Jose Maria ;

Fogelstrand, Linda ;

Goemans, Bianca F. ;

Hasle, Henrik ;

Jonsson, Olafur G. ;

Kovalova, Zhanna ;

Munthe-Kaas, Monica C. ;

Noren-Nystrom, Ulrika ;

Palmu, Sauli ;

Pasauliene, Ramune ;

Saks, Kadri ;

Tierens, Anne Maria ;

Turkiewicz, Dominik ;

Pronk, Cornelis Jan .

BLOOD, 2023, 142

[49] A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML) [J].

Vyas, Paresh ;

Daver, Naval ;

Chao, Mark ;

Xing, Guan ;

Renard, Camille ;

Ramsingh, Giri ;

Sallman, David .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S247-S247

[50] Efficacy and Safety of Single-Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial [J].

Cortes, J. E. ;

Khaled, S. K. ;

Martinelli, G. ;

Perl, A. E. ;

Ganguly, S. ;

Russell, N. H. ;

Kramer, A. ;

Dombret, H. ;

Hogge, D. ;

Jonas, B. A. ;

Leung, A. Y. -H. ;

Mehta, P. ;

Montesinos, P. ;

Radsak, M. P. ;

Sica, S. ;

Arunachalam, M. ;

Holmes, M. ;

Kobayashi, K. ;

Namuyinga, R. ;

Ge, N. ;

Yver, A. ;

Zhang, Y. ;

Levis, M. J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 :78-78

← 1 2 3 4 5 →